Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 7
Submit an article Journal homepage
179
Views
45
CrossRef citations to date
0
Altmetric
Review

Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology

Patricia M LoRusso Barbara Ann Karmanos Cancer Institute/ Wayne State University, Hudson-Webber
, DO &
Joseph Paul Eder Clinical Research Discovery Medicine Oncology, AstraZeneca LP, 35 Gatehouse Drive, Waltham, MA 02451, USA +1 781 839 4582; +1 781 839 4550; [email protected]
, MD
Pages 1013-1028 | Published online: 12 Jun 2008

Bibliography

  • Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:6829-37
  • Ali S, Ali S. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). Gene 2007;401:38-45
  • Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005;5:689-98
  • Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433-9
  • Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21
  • Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-74
  • Zhang YW, Su Y, Volpert OV, et al. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 2003;100:12718-23
  • Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat Rev 2006;5:730-9
  • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32
  • Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58
  • Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21(12):2237-46
  • Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366(9496):1527-37
  • Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000;60(Suppl 1):15-23; discussion 41-12
  • Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7(10):2958-70
  • Woodburn JR, Wakeling A, Kelly H, Dyroff M. Preclinical studies with the oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (‘Iressa’) demonstrate significant anti-tumor activity. Presented at the Signal Transduction Pathways and Regulation of Gene Expression as Therapeutic Targets meeting; 2000 Jan 26 – 29; Luxembourg
  • Kelly HC, Laight A, Morris CQ, et al. Phase I data of ZD1839–an oral epidermal growth factor receptor tyrosine kinase inhibitor [abstract 419]. Ann Oncol 1998;9(2):S109
  • Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a Phase I trial. J Clin Oncol 2002;20(9):2240-50
  • Steeghs N, Nortier JW, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol 2007;14(2):942-53
  • Cappuzzo F, Finocchiaro G, Metro G, et al. Clinical experience with gefitinib: an update. Crit Rev Oncol Hematol 2006;58(1):31-45
  • Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10(4):1212-8
  • Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial - INTACT 1. J Clin Oncol 2004;22(5):777-84
  • Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004;22(5):785-94
  • Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin 2006;22(3):561-73
  • Kim TE, Murren JR. Erlotinib OSI/Roche/Genentech. Curr Opin Investig Drugs 2002;3(9):1385-95
  • Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19(13):3267-79
  • Erlotinib (Tarceva™) package insert. OSI Pharmaceuticals, Inc. & Genentech, Inc. 2005
  • Herbst RS. Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol 2003;30(3 Suppl 7):34-46
  • Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer 2004;6(Suppl 1):S20-23
  • Cohen MH, Johnson JR, Chen YF, et al. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 2005;10(7):461-6
  • Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG] [abstract 1]. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(16S Suppl)
  • Moore MJ. Brief communication: a new combination in the treatment of advanced pancreatic cancer. Semin Oncol 2005;32(6 Suppl 8):5-6
  • Cascone T, Gridelli C, Ciardiello F. Combined targeted therapies in non-small cell lung cancer: a winner strategy? Curr Opin Oncol 2007;19(2):98-102
  • Ye C, Sweeny D, Sukbuntherng J, et al. Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416. Toxicol In Vitro 2006;20(2):154-62
  • Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005;315(3):971-9
  • O'donnell A, Padhani A, Hayes C, et al. A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer 2005;93(8):876-83
  • Heymach JV, Desai J, Manola J, et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 2004;10(17):5732-40
  • Peterson AC, Swiger S, Stadler WM, et al. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res 2004;10(12 Pt 1):4048-54
  • Stadler WM, Cao D, Vogelzang NJ, et al. A randomized phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res 2004;10(10):3365-70
  • Lockhart AC, Cropp GF, Berlin JD, et al. Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. Am J Clin Oncol 2006;29(2):109-15
  • Dowlati A, Robertson K, Radivoyevitch T, et al. Novel phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin Cancer Res 2005;11(21):7938-44
  • Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65(10):4389-400
  • Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004;7(3):193-201
  • Horowitz JR, Rivard A, Van Der Zee R, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 1997;17(11):2793-800
  • Yang R, Thomas GR, Bunting S, et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 1996;27(6):838-44
  • Drevs J, Medinger M, Mross K, et al. Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors [abstract 3002]. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(16S Suppl)
  • Jost LM, Gschwind HP, Jalava T, et al. Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients. Drug Metab Dispos 2006;34(11):1817-28
  • Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21(21):3955-64
  • Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 2005;16(4):558-65
  • Tyagi P. Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. Clin Colorectal Cancer 2005;5(1):24-6
  • Kohne C, Bajetta E, Lin E, et al. Final results of CONFIRM 2: A multinational, randomized, double-blind, Phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo [abstract 4033]. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl)
  • Mross K, Drevs J, Muller M, et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 2005;41(9):1291-9
  • Thomas AL, Morgan B, Horsfield MA, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005;23(18):4162-71
  • Gauler TC, Besse B, Meric JB, et al. Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily or twice daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) [abstract 7541].2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl)
  • Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002;21(41):6255-63
  • Burris HA, 3RD, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23(23):5305-13
  • Adams VR, Bence AK, Anderson EB, et al. A Phase I pharmacokinetic/pharmacodynamic study evaluating multiple doses of oral GW572016 in healthy subjects [abstract 374]. Proc Am Soc Clin Oncol 2002;21
  • Reid A, Vidal L, Shaw H, De Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007;43(3):481-9
  • Spector NL, Blackwell K, Hurley J, et al. EGF103009, a Phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response [abstract 502]. Proc Am Soc Clin Oncol 2006;24
  • Cristofanilli M, Boussen H, Baselga J, et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC) [abstract 1]. Breast Cancer Res Treat 2006;100
  • lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer [abstract 503]. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S Suppl)
  • Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733-43
  • US Food and Drug Administration. FDA approves tykerb for advanced breast cancer patients, 2007. Available from: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01586.html [Last accessed 16 May 2008]
  • Cameron D, Stein S, Zaks T, et al. Lapatinib plus capecitabine shows superior efficacy compared to capecitabine alone in patients with ErbB2 positive advanced or metastatic breast cancer - initial biomarker data [abstract 2]. Breast Cancer Res Treat 2006;100
  • Tuma RS. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials. J Natl Cancer Inst 2007;99(5):348-9
  • Colomer R, Montero S, Lluch A, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000;6(6):2356-62
  • Abdollahi A, Lipson KE, Sckell A, et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 2003;63(24):8890-8
  • Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18(2):338-40
  • Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111(9):1287-95
  • Sessa C, Vigano L, Grasselli G, et al. Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. Eur J Cancer 2006;42(2):171-8
  • Kuenen BC, Giaccone G, Ruijter R, et al. Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clin Cancer Res 2005;11(17):6240-6
  • Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9(1):327-37
  • Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25(7):884-96
  • Bello CL, Sherman L, Zhou J, et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drug 2006;17(3):353-8
  • Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24(1):25-35
  • Demetri GD, Van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368(9544):1329-38
  • Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295(21):2516-24
  • Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16-24
  • Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev 2006;5(10):835-44
  • Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11(15):5472-80
  • Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16(10):1688-94
  • Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92(10):1855-61
  • Rini BI: Stabilization of disease in patients with metastatic renal cell carcinoma using sorafenib. Nat Clin Prac 2006;3(11):602-3
  • Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(16):2505-12
  • Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62(24):7284-90
  • Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62(16):4645-55
  • Herbst RS, Heymach JV, O'reilly MS, et al. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drug 2007;16(2):239-49
  • Ryan AJ, Wedge SR. ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 2005;92(Suppl 1):S6-13
  • Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004;10(2):784-93
  • Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9(4):1546-56
  • Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16(8):1391-7
  • Minami H, Ebi H, Tahara M, et al. A Phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors [abstract 778]. Proc Am Soc Clin Oncol 2003;22
  • Davis DW, Takamori R, Raut CP, et al. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin Cancer Res 2005;11(2 Pt 1):678-89
  • Heymach JV, Johnson BE, Prager D, et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: follow-up results [abstract 7016]. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S Suppl)
  • Heymach J, West H, Kerr R, et al. ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: results of the run-in phase of a two-part randomized phase II study. Lung Cancer 2005;49(Suppl 2):S247
  • Johnson BE MAP, West H, et al. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC [abstract 7102].2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(16S Suppl)
  • Kovacs MJ, Reece DE, Marcellus D, et al. A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma – NCIC CTG IND.145. Invest New Drug 2006;24(6):529-35
  • Heymach JV, Johnson BE, Rowbottom JA, et al. A randomized, placebo-controlled Phase II trial of ZD6474 plus docetaxel, in patients with NSCLC [abstract 3023]. J Clin Oncol 2005;23(16S Suppl)
  • Natale RB, Bodkin D, Govindan R, et al. ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized Phase II trial [abstract 7000]. J Clin Oncol 2006;24(18S Suppl)
  • Natale R, Bodkin D, Govindan G, et al. A comparison of the antitumour efficacy of ZD6474 and gefitinib (Iressa(TM)) in patients with NSCLC: results of a randomized, double-blind phase II study. Lung Cancer 2005;49(Suppl 2): S36
  • Nakagawa K, Kiura K, Shinkai T, et al. A randomized double-blind Phase IIa dose-finding study of ZD6474 in Japanese patients with NSCLC [abstract 7067]. J Clin Oncol 2006;24(18S Suppl)
  • Wells S, You YN, Lakhani V, et al. A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer [abstract 5533]. J Clin Oncol 2006;24(18S Suppl)
  • Miller KD, Trigo JM, Wheeler C, et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005;11(9):3369-76
  • Gridelli C. Targeted therapies and non-small-cell lung cancer: new developments. Curr Opin Oncol 2007;19(2):75-7
  • Sikic BI, Wakelee HA, Adjei AA, et al. A Phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally to patients with advanced solid malignancies (ASM) [abstract 342]. Eur J Cancer Suppl 2006;4(12):106-7
  • Lorusso P, Appleman L, Zhu A, et al. Pharmacodynamics (pd) of x1880, a novel spectrum selective kinase inhibitor (SSKI), administered orally to patients (pts) with advanced solid tumors (AST) [abstract 404]. Eur J Cancer Suppl 2006;4(12):124
  • Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006;6(8):637-45
  • Bottaro DP, Liotta LA. Cancer: out of air is not out of action. Nature 2003;423(6940):593-5
  • Xin X, Yang S, Ingle G, et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 2001;158(3):1111-20
  • Gerritsen ME, Tomlinson JE, Zlot C, et al. Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br J Pharmacol 2003;140(4):595-610
  • Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7(9):987-9
  • Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6(8):583-92

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.